Director Bruce Polsky of Atea Pharmaceuticals, Inc. filed a Form 144 notice on November 18, 2026, disclosing a proposed sale of 18,252 shares of common stock on NASDAQ under SEC Rule 144.
Key Highlights
- Proposed sale: 18,252 shares of Atea Pharmaceuticals common stock, with an aggregate market value of $72,099.05, according to the filing.
- Seller: Bruce Polsky, identified in the filing as a Director of Atea Pharmaceuticals, Inc.
- Acquisition: The shares were acquired on November 18, 2026, via a stock option exercise from the issuer, with payment made in cash.
- Approximate sale date: November 18, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
- Recent prior sales: Polsky sold 8,720 shares on November 17, 2026, for gross proceeds of $35,155.55, and 14,254 shares on November 16, 2026, for gross proceeds of $60,840.35, as disclosed in the past three months' sales table.
- Shares outstanding: The filing reports 80,304,145 shares of common stock outstanding.
Polsky's Proposed Disposition and Recent Transaction History at Atea Pharmaceuticals
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Bruce Polsky, a director of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), intends to sell 18,252 shares of the company's common stock. The filing lists an aggregate market value of $72,099.05 for the proposed sale. The notice was dated November 18, 2026, and the approximate date of sale is listed as November 18, 2026.
The filing discloses that the 18,252 shares to be sold were acquired on November 18, 2026, through a stock option exercise from the issuer, with payment described as cash. The proposed transaction is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on the NASDAQ exchange.
In the section covering securities sold during the prior three months, the filing lists two additional transactions by Polsky: 8,720 shares sold on November 17, 2026, generating gross proceeds of $35,155.55, and 14,254 shares sold on November 16, 2026, generating gross proceeds of $60,840.35. By signing the notice, Polsky represented, as stated in the filing, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."
What Was Disclosed
Atea Pharmaceuticals director Bruce Polsky filed a Form 144 notice proposing to sell 18,252 shares of common stock, acquired via stock option exercise, with an aggregate market value of $72,099.05, through Morgan Stanley Smith Barney LLC on NASDAQ on November 18, 2026.





Please wait processing your request...